{"id":305308,"date":"2023-10-13T00:00:00","date_gmt":"2023-10-13T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0016-2023-biopharma-type-2-diabetes-access-reimbursement-access-reimbursement-type-2\/"},"modified":"2026-03-31T10:31:57","modified_gmt":"2026-03-31T10:31:57","slug":"acremd0016-2023-biopharma-type-2-diabetes-access-reimbursement-access-reimbursement-type-2-diabetes-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0016-2023-biopharma-type-2-diabetes-access-reimbursement-access-reimbursement-type-2-diabetes-us\/","title":{"rendered":"Type 2 Diabetes – Access & Reimbursement – Access & Reimbursement – Type 2 Diabetes (US)"},"content":{"rendered":"

The sodium-glucose cotransporter-2 (SGLT<\/abbr>-2) inhibitors and glucagon-like peptide-1 (GLP<\/abbr>-1) receptor agonists are frequently prescribed for type 2 diabetes (T2D<\/abbr>). These classes, along with glucose-dependent insulinotropic polypeptide (GIP<\/abbr>) \/ GLP<\/abbr>-1 receptor agonists, have demonstrated strong efficacy and safety data and offer cardiovascular, renal, and weight management benefits to T2D<\/abbr> patients. Eli Lilly\u2019s first-in-class GIP<\/abbr> \/ GLP<\/abbr>-1 receptor agonist, Mounjaro, launched in the United States in June 2022 and is well received by physicians owing to its hugely positive clinical evidence; the use of Novo Nordisk\u2019s oral Rybelsus is supported by its advantages over SC<\/abbr>-administered GLP<\/abbr>-1 receptor agonists; the growing demand for GLP<\/abbr>-1 receptor agonists like Novo Nordisk\u2019s Ozempic has led to shortages and created new challenges for payers and physicians in managing their use. The increasing use of these high-priced branded drugs has created a restrictive market access environment that often relegates their use to the second or later lines of T2D<\/abbr> treatment.<\/p>\n

QUESTIONS ANSWERED<\/strong><\/p>\n